めまい治療の市場規模、シェア、成長分析：タイプ別、治療法別、エンドユーザー別、地域別 - 産業予測 2025～2032年

めまい治療の世界市場規模は2023年に18億3,000万米ドルと評価され、2024年の19億2,000万米ドルから2032年には28億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.1％で成長する見通しです。

回転や移動の感覚を特徴とするめまいは、世界的に個人への影響が拡大しており、めまい治療市場の需要急増を促しています。この動向は、めまいの罹患率の上昇とヘルスケア支出の増加が主な要因です。さらに、高齢化社会が拡大するにつれて、特に高齢者人口が多い国ではめまいのリスクが高まっています。めまいの症状や治療に対する認識が高まり、医学研究への投資も増加していることから、長期的な市場成長が期待されます。さらに、良くない生活習慣の蔓延が、効果的なめまい治療への需要を煽っています。これらの要因を総合すると、急速に進化するヘルスケアの状況において、めまい医療を提供する企業にとって有望なビジネスチャンスとなります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

めまい治療市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 良性発作性頭位めまい症（BPPV）
• 内耳炎
• 前庭神経炎
• メニエール病

めまい治療市場規模：治療法別& CAGR（2025-2032）

• 市場概要
• 抗コリン薬
• 抗ヒスタミン薬
• ベンゾジアゼピン
• その他

めまい治療市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• その他

めまい治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Abbott Laboratories（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• GlaxoSmithKline plc（UK）
• Merck & Co., Inc.（USA）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Boehringer Ingelheim GmbH（Germany）
• AstraZeneca plc（UK）
• Bristol-Myers Squibb Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Limited（India）
• Lupin Limited（India）

結論と提言

Global Vertigo Treatment Market size was valued at USD 1.83 billion in 2023 and is poised to grow from USD 1.92 billion in 2024 to USD 2.86 billion by 2032, growing at a CAGR of 5.1% during the forecast period (2025-2032).

Vertigo, characterized by sensations of spinning or movement, is increasingly affecting individuals globally, prompting a surging demand in the vertigo treatment market. This trend is largely driven by the rising incidence of vertigo and escalating healthcare expenditures. Additionally, as the aging population expands, the risk of vertigo intensifies, particularly in countries with significant elderly demographics. Increased awareness of vertigo symptoms and treatments, alongside growing investments in medical research, is expected to bolster market growth in the long-term. Furthermore, the prevalence of poor lifestyle habits is fueling the demand for effective vertigo treatments. Collectively, these factors present promising opportunities for vertigo treatment providers in a rapidly evolving healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vertigo Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vertigo Treatment Market Segments Analysis

Global Vertigo Treatment Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Benign Paroxysmal Positional Vertigo (BPPV), Labyrinthitis, Vestibular Neuronitis and Meniere's Disease. Based on Treatment, the market is segmented into Anticholinergics, Antihistamines, Benzodiazepines and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vertigo Treatment Market

The global vertigo treatment market is significantly influenced by the increasing number of elderly individuals worldwide. As the aging population grows, so does the likelihood of experiencing vertigo, making this demographic a crucial driver of demand for vertigo treatments. With a higher incidence of vertigo associated with advancing age, healthcare providers are compelled to address the needs of this expanding geriatric population. This trend underscores the importance of developing effective treatment options and healthcare solutions tailored to the aging demographic, ultimately contributing to the overall growth of the market for vertigo treatments on a global scale.

Restraints in the Global Vertigo Treatment Market

The Global Vertigo Treatment market faces significant challenges due to the potential side effects associated with vertigo medications, which may include constipation, dizziness, insomnia, headaches, and fatigue. These adverse reactions can deter individuals from seeking pharmacological treatment for their condition, leading to reluctance in medication adherence and overall treatment. As a result, patients may opt for alternative therapies or choose to forego treatment altogether, which can restrict market growth and limit the adoption of effective solutions. Addressing these concerns is crucial for improving patient compliance and expanding the reach of vertigo treatment options in the global market.

Market Trends of the Global Vertigo Treatment Market

The Global Vertigo Treatment market is experiencing a significant shift towards novel diagnostic and drug delivery innovations, driving its growth. As advancements in diagnostic technologies emerge, companies are harnessing these tools to enhance accuracy and efficiency in identifying vertigo causes, ultimately boosting revenue potential. In addition, the adoption of cutting-edge drug delivery methods is gaining traction among treatment providers, enabling targeted medication delivery that minimizes side effects and maximizes therapeutic efficacy. This trend reflects the industry's commitment to improving patient outcomes and optimizing treatment protocols, positioning the market for sustained growth and responsiveness to evolving healthcare demands through 2023 and beyond.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Vertigo Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Benign Paroxysmal Positional Vertigo (BPPV)
• Labyrinthitis
• Vestibular Neuronitis
• Meniere's Disease

Global Vertigo Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anticholinergics
• Antihistamines
• Benzodiazepines
• Others

Global Vertigo Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Others

Global Vertigo Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations